 |
|
 |
1st
EMBL/EMBO Joint Conference 2000 |
|
|
Programme |
|
|
| Developing new dialogue |
|
|
|
Keynote Lecture
Session I
Session II
Session III
Session IV |
|
| Keynote Lecture |
|
|
|
Technology and human reproduction: 1950-2050
Carl Djerassi, Stanford University, USA |
|
| Session I |
|
|
|
From Science to Society
Lewis Wolpert, Professor of Biology as Applied
to Medicine, University College London, UK |
|
|
Case studies
A retrospective on specific issues where the checks and balances that are in place have worked and/or failed |
|
From Pan to pandemic: HIV and AIDS
Robin Weiss, University College London, UK
The Saga of BSE
John Collinge, Imperial College, London, UK |
|
|
Risk studies Theory
and practice |
|
Why framing processes in risk science are important: but still neglected
Brian Wynne, Lancaster University, UK
Framing public perceptions of risk: agricultural GMOs in Europe
Claire Marris, University of Versailles, France
Panel discussion:
how to restore public trust in science
Maynard Olson [Chair], University of Washington, USA
Beate Weber, Lady Major of Heidelberg, Germany
Tom Wilkie, Wellcome Trust, UK
Julian Kinderlerer , Sheffield University, UK
Orla Smith, Science, USA
Maurizio Laccarino, International Institute of Genetics and Biophysics, Italy |
|
| Session II |
|
|
|
Medical uses of genetic information: gene therapy, prenatal diagnostics, and population genetics
Jens Reich [Chair], Max-delbrück-Centrum, Germany
From the sequence of our genes to medical utility
Andrea Ballabio, TIGEM, Italy
The social costs of better disease treatments
Peter Goodfellow, SmithKleine Beecham Pharmaceuticals,
UK
Genetic research and common diseases
Karl Stefánsson, deCode Genetics, Iceland |
|
| Session III |
|
|
|
On human genome projects: uses and abuses
John Collinge [Chair], Imperial College London, UK
The genomic turn: is the genome the new name of the soul?
Alexandre Mauron, University of Geneva
Debating human identity: institutional commitments and consequences
Sheila Jasanoff, Harvard University, USA
The human genome project: a scientist's view of what went right and what went wrong
Maynard Olson, University of Washington, USA
Past and future of behavioural genetics
Benno Müller-Hill, University of Cologne,
Germany
Panel discussion:
public understanding of genetic information
Alastair Kent [Chair], Genetic Interest Group, UK
Barbara Cohen, Ludwig Institute of Cancer Research, USA
Jean Louis Mandel, IGBMC, France
Alexandre Mauron, University of Geneva, Switzerland
Vivienne Parry, BBC, UK
Presentation of GEOD journalism award for Human Genetics |
|
| Session IV |
|
|
|
Biotechnology, bio-industry, bio-business
Charles Kurland [Co-Chair], BMC, Sweden and Chris Leaver [Co-Chair], Oxford University, UK
Business with biotech: Europe vs. USA ' reality vs. wishful thinking
Friedrich von Bohlen, lion Bioscience AG, Germany
Biotechnology at the beginning of the third millennium: facts and global trends
Manfred Kern, Aventis, Germany
Antibiotics for the 21st century
Julian Davies, University of British Colombia, Canada
Defending animal use in biotechnology
Alan Colman, PPL Therapeutics
Panel discussion: biotechnology and its discontents
Julian Kinderlerer [Chair], Sheffield University, UK
Hans-Jörg Rheinberger, MPI History of Science, Germany
Mark Cantley, European Commission, Belgium
Sheila jasanoff, Harvard University, USA
Stefan Flothmann, Greenpeace, Germany
David Dickinson, Nature, UK
Science
in the spotlight
Julian Kinderlerer [Chair], Sheffield University,
UK
Science in theater: an historical account
Ivo Schneider, Bunderswehr Universität, Munich,
Germany
Science in theater
Carl Djerassi, Stanford University, USA |
|
|
|
